Eton Pharmaceuticals, Inc. ETON Increlex — Contract With Customer Liability Revenue Recognized
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Eton Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityRevenueRecognized.
The official record: Eton Pharmaceuticals, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Eton Pharmaceuticals, Inc.'s increlex — contract with customer liability revenue recognized.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Eton Pharmaceuticals, Inc.'s increlex — contract with customer liability revenue recognized?
- Eton Pharmaceuticals, Inc. (ETON) reported increlex — contract with customer liability revenue recognized of $158K in Q1 2026.
- How has Eton Pharmaceuticals, Inc.'s increlex — contract with customer liability revenue recognized changed year-over-year?
- Eton Pharmaceuticals, Inc.'s increlex — contract with customer liability revenue recognized increased by 96.3% year-over-year, from $80.5K to $158K.
- What does increlex — contract with customer liability revenue recognized mean?
- The amount of revenue previously recorded as a contract liability that has been recognized in the current period upon the satisfaction of performance obligations for Increlex. This metric bridges the gap between cash received in advance and actual earnings reported on the income statement. It reflects the successful execution of service or product delivery commitments.